Viral infections in the biologic therapy era

References

• Singh J, Wells G, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and cochrane overview (review). Cochrane Database Syst Rev. 2016;(2). Art. No:CD008794:1–86.
   PubMedGoogle Scholar
• Davies HD. Infectious complications with the use of biologic response modifiers in infants and children. Pediatrics. 2016;138(2):e1–e21.
   Web of Science ®Google Scholar
• Bonilla-Hernán MG, Miranda-Caru ME, Martin-Mola E. Review new drugs beyond biologics in rheumatoid arthritis : the kinase inhibitors. Rheumatology. 2011;50(May):1542–1550.
   PubMedGoogle Scholar
• Lahiri M, Dixon WG. Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. Best Pract Res Clin Rheumatol [Internet]. 2015;29(6):826–842. DOI:10.1016/j.berh.2015.05.009.
   PubMed Web of Science ®Google Scholar
• Shale MJ, Seow CH, Coffin CS, et al. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31(1):20–34.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spano F, Contatore M, et al. Infection risk associated with anti-TNF- a agents : a review. Expert Opin Drug Saf. 2015;14(4):571–582.
   PubMed Web of Science ®Google Scholar
• Fernández-Ruiz M, Meije Y, Manuel O, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (introduction). Clin Microbiol Infect. 2018. DOI:10.1016/j.cmi.2018.01.029.
   Google Scholar
• Baddley JW, Cantini F, Goletti D, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies : an infectious diseases perspective (soluble immune effector molecules [I]: anti-tumour necrosis factor- a agents). Clin Microbiol Infect. 2018. DOI:10.1016/j.cmi.2017.12.025.
   PubMedGoogle Scholar
• Winthrop KL, Mariette X, Silva JT, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [II]: agents targeting interleukins, immunoglobuli. Clin Microbiol Infect. [Internet]. 2018. DOI:10.1016/j.cmi.2018.02.002
   PubMedGoogle Scholar
• Aguilar-Company J, Fernández-Ruiz M, García-Campelo R, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biologic therapies : an infectious diseases perspective d cell surface receptors and associated signaling pathways. Clin Microbiol Infect. 2018. DOI:10.1016/j.cmi.2017.12.027
   PubMedGoogle Scholar
• Reinwald M, Silva JT, Mueller NJ, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect [Internet]. 2018. DOI:10.1016/j.cmi.2018.02.009
   PubMedGoogle Scholar
• Mikulska M, Lanini S, Gudiol C, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies : an infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect. 2018. DOI:10.1016/j.cmi.2018.02.003
   Google Scholar
• Drgona L, Gudiol C, Lanini S, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33. Clin Microbiol Infect. 2018. DOI:10.1016/j.cmi.2018.03.022
   Google Scholar
• Redelman-Sidi G, Michielin O, Cervera C, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1- phosphate rec. Clin Microbiol Infect. 2018. DOI:10.1016/j.cmi.2018.01.030.
   PubMedGoogle Scholar
• Woodrick RS, Ruderman EM. Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol [Internet]. 2011;7(11):639–652. DOI:10.1038/nrrheum.2011.145.
   PubMed Web of Science ®Google Scholar
• Ramelyte E, Schindler SA, Dummer R. The safety of anti PD-1 therapeutics for the treatment of melanoma. Expert Opin Drug Saf [Internet]. 2016. DOI:10.1080/14740338.2016.1248402
   PubMed Web of Science ®Google Scholar
• Rao AM, Valentini D, Dodoo E, et al., Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Int J Infect Dis [Internet]. 2017. DOI:10.1016/j.ijid.2017.01.028
   Google Scholar
• Zachou K, Sarantopoulos A, Gatselis NK, et al. Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression : a hidden threat. World J Hepatol. 2013;5(7):387–392.
   PubMedGoogle Scholar
• De Nard F, Todoerti M, Grosso V, et al. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment : extending perspective from old to newer drugs. World J Hepatol. 2015;7(3):344–361.
   PubMed Web of Science ®Google Scholar
• Feld JJ. Hepatitis B reactivation : the controversies continue. Dig Dis. 2017;35:351–358.
   PubMed Web of Science ®Google Scholar
• Hsiao L, Chiou T, Gau J, et al. Risk of reverse seroconversion of Hepatitis B virus surface antigen in non-hodgkin lymphoma patients. Med. 2015;94(32):1–12.
   Web of Science ®Google Scholar
• Huang Y, Hsiao L, Hong Y, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31(22):2765–2772.
   PubMed Web of Science ®Google Scholar
• Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152:1297–1309.
   PubMed Web of Science ®Google Scholar
• Vassilopoulos D. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes. Eur J Intern Med. 2011;22(6):572–575. Internet. DOI:10.1016/j.ejim.2011.09.001.
   PubMed Web of Science ®Google Scholar
• Tzeng H, Tsai H, Chyuan I, et al. Tumor necrosis factor-alpha induced by Hepatitis B virus core mediating the immune response for Hepatitis B viral clearance in mice model. PLoS One. 2014;9(7):1–8.
   Web of Science ®Google Scholar
• Yeo W, Chan PKS, Zhong S, et al. Frequency of Hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy : a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;307(March):299–307.
   Google Scholar
• Pérez-Alvarez R, Diaz-Lagares C, García-Hernández F, et al. Hepatitis B Virus (HBV) reactivation in patients receiving analysis of 257 cases. Med. 2011;90(6):359–371.
   PubMed Web of Science ®Google Scholar
• Barone M, Notarnicola A, Lopalco G, et al. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved Hepatitis B viral infection. Hepatology. 2015;62:40–46.
   PubMed Web of Science ®Google Scholar
• Göksu SS, Ş B, Coşkun HŞ. Hepatitis B reactivation related to everolimus. World J Hepatol. 2013;5(1):43–45.
   PubMedGoogle Scholar
• Teng C, Wu H, Tsai H, et al. Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for Hepatitis B virus tumorigenesis and therapy. Hepatology. 2011;54:1199–1207.
   PubMed Web of Science ®Google Scholar
• Lai G, Yan S, Chang C, et al. B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol. 2013;19(8):1318–1321.
   PubMed Web of Science ®Google Scholar
• Hammond ASP, Chen K, Pandit A, et al. Risk of Hepatitis B virus reactivation in patients treated with ibrutinib. Blood. 2018;131(17):1987–1989.
   PubMed Web of Science ®Google Scholar
• Lan J, Chen Y, Hsieh T, et al. Kinetics of viral loads and risk of Hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011;70:1719–1725.
   PubMed Web of Science ®Google Scholar
• Perrillo RP, Gish R, Falck-Ytter YT, et al. American gastroenterological association institute technical review on prevention and treatment of Hepatitis B reactivation during immunosuppressive drug therapy. Gastroenterology [Internet]. 2015;148:221–244. DOI:10.1053/j.gastro.2014.10.038
   PubMed Web of Science ®Google Scholar
• Law MF, Ho R, Cheung CKM, et al. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World J Gastroenterol. 2016;22(28):6484–6500.
   PubMed Web of Science ®Google Scholar
• Mallet V, Doerig C, Pischke S, et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation : recommendations of the 5th European conference on infections in Leukaemia (ECIL-5). Lancet Infect Dis. 2016;16(May):606–617.
   PubMedGoogle Scholar
• Fukuda R, Ishimura N, Ishihara S, et al. Intrahepatic expression of pro-inflammatory cytokirk mRNAs and i nterferon efficacy in chronic hepatitis C. Liver. 1996;16:390–399.
   PubMedGoogle Scholar
• Brunasso AMG, Puntoni M, Gulia A, et al. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection : a systematic review. Rheumatology. 2011;50(June):1700–1711.
   PubMedGoogle Scholar
• Sagnelli E, Pisaturo M, Sagnelli C, et al. Rituximab-based treatment, HCV replication, and Hepatic Flares. Clin Dev Immunol. 2012;1–5. ID949950
   Google Scholar
• Yazici O, Ali M, Şendur N, et al. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol. 2014;20(22):6716–6724.
   PubMed Web of Science ®Google Scholar
• Chayama K, Imamura M, Hayes CN. Hepatitis C virus treatment update - A new era of all-oral HCV treatment. Adv Dig Med [Internet]. 2016;3(4):153–160. DOI:10.1016/j.aidm.2016.03.002.
   Web of Science ®Google Scholar
• Kowalsky S, Arnon R, Prevention PR, et al. Prevention of cytomegalovirus following solid organ transplantation : a literature review. Pediatr Transplant. 2013;17:499–509.
   PubMed Web of Science ®Google Scholar
• Andrassy J, Hoffmann VS, Rentsch M, et al. Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor Y based immunosuppression? A systematic review. Transplantation. 2012;94(12):1208–1217.
   PubMed Web of Science ®Google Scholar
• Tedesco-Silva H, Felipe C, Ferreira A, et al. Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses. Am J Transplant. 2015;15:2655–2664.
   PubMed Web of Science ®Google Scholar
• Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma. 2007;48(July):1307–1312.
   PubMedGoogle Scholar
• Kuo C, Wu C, Ho H, et al. Detection of cytomegalovirus reactivation in cancer patients receiving chemotherapy. Clin Microbiol Infect. 200814(3):221-7.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25(35):5616–5623.
   PubMed Web of Science ®Google Scholar
• Clerico M, De MS, Artusi CA, et al. CMV infection in two patients with multiple sclerosis treated with alemtuzumab. Mult slcerosis. 2017;23(6):874–876.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Fowler NH. Idelalisib in the management of lymphoma. Blood. 2018;128(3):331–337.
   Web of Science ®Google Scholar
• Prestes ADP, Arbona E, Nevett-Fernandez A, et al. Dasatinib use and risk of cytomegalovirus reactivation after allogeneic hematopoietic-cell transplantation. Clin Infect Dis. 2017;65:510–513.
   PubMed Web of Science ®Google Scholar
• Haerter G, Manfras BJ, De J-HY, et al. Cytomegalovirus retinitis in a patient treated with anti – tumor necrosis factor alpha antibody therapy for Rheumatoid Arthritis. Clin Infect Dis. 2004;39:88–94.
   Web of Science ®Google Scholar
• Kohara M, Cytomegalovirus Ileitis BR. Hemophagocytic syndrome associated with use of anti– tumor necrosis factor–a antibody. Clin Infect Dis. 2006;42:733–734.
   PubMed Web of Science ®Google Scholar
• Sari I, Birlik M, Gonen C, et al. Cytomegalovirus colitis in a patient with Behcet ’ s disease receiving tumor necrosis factor alpha inhibitory treatment. World J Gastroenterol. 2008;14(18):2912–2914.
   PubMed Web of Science ®Google Scholar
• Pillet S, Jarlot C, Courault M, et al. Infliximab does not worsen outcomes during flare-ups associated with cytomegalovirus infection in patients with ulcerative colitis selection of patients. Inflamm bowel Dis. 2015;21(7):1580–1586.
   PubMed Web of Science ®Google Scholar
• Taniguchi D, Takahara O, Takasaki Y, et al. Fatal cytomegalovirus pneumonia and associated herpes virus infection in a relapsed/refractory multiple myeloma patient treated with bortezomib plus. Case Rep Oncol. 2009;2:140–143.
   PubMedGoogle Scholar
• Österborg A, Foà R, Bezares R, et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia. 2009;23:1980–1988.
   PubMed Web of Science ®Google Scholar
• Yun H, Xie F, Delzell E, et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res. 2015;67(5):731–736.
   PubMed Web of Science ®Google Scholar
• Che H, Lukas C, Morel J, et al. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Jt Bone Spine. [Internet]. 2014;81(3):215–221. DOI:10.1016/j.jbspin.2013.07.009.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Baddley JW, Delzell E, et al. Association between the initiation of anti – tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309(9):887–895.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with Rheumatoid Arthritis. Arthritis Rheumatol. 2014;66(10):2675–2684.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1843–1847.
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis [Internet]. 2009;49(8):1211–1225. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19769539.
   PubMed Web of Science ®Google Scholar
• Arvin AM, Wolinsky JS, Kappos L, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015;72(1):31–39.
   PubMed Web of Science ®Google Scholar
• Tran CT, Ducancelle A, Masson C, et al. Herpes zoster: risk and prevention during immunomodulating therapy. Jt Bone Spine. 2017;84(1):21-27.
   PubMed Web of Science ®Google Scholar
• Adelzadeh L, Jourabchi N, Wu JJ. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. J Eur Acad Dermatology Venereol [Internet]. 2014;28(7):846–852. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25081573%5Cnhttp://doi.wiley.com/10.1111/jdv.12307.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xie FL, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308(1):43–49.
   PubMed Web of Science ®Google Scholar
• Cunningham AL. The herpes zoster subunit vaccine. Expert Opin Biol Ther. 2016;16(2):265–271.
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Heineman T. Vaccine profile of herpes zoster (HZ/su) subunit vaccine. Expert Rev Vaccines [Internet]. 2017;16(7):1–10. DOI:10.1080/14760584.2017.1329012.
   PubMed Web of Science ®Google Scholar
• Bradford RD, Pettit AC, Wright PW, et al. Herpes simplex encephalitis during treatment with tumor necrosis factor–α inhibitors. Clin Infect Dis [Internet]. 2009;49:924–927. Available from: http://cid.oxfordjournals.org/lookup/doi/10.1086/605498
   PubMed Web of Science ®Google Scholar
• Rhj C, Singson SV, Haroun F, et al. Herpes simplex virus encephalitis during treatment with etanercept. Scand J Infect Dis. 2014;46(2):152–154 [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24228826%5Cnhttp://www.tandfonline.com/doi/full/10.3109/00365548.2013.849816%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/24228826%5Cnhttp://www.tandfonline.com/doi/full/10.3109/00365548.2013.849816.
   PubMedGoogle Scholar
• Justice EA, Khan SY, Logan S, et al. Disseminated cutaneous herpes simplex virus-1 in a woman with rheumatoid arthritis receiving infliximab: a case report. J Med Case Rep [Internet]. 2008;2:282. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2542400&tool=pmcentrez&rendertype=abstract
   PubMedGoogle Scholar
• San-Juan R, Comoli P, Caillard S, et al. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. Clin Microbiol Infect [Internet]. 2014;20(s7):109–118. DOI:10.1111/1469-0691.12534.
   PubMedGoogle Scholar
• Pascual J, Royuela A, Fernández AM, et al. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients. Transpl Infect Dis [Internet]. 2016;18(March):819–831. DOI:10.1111/tid.12601
   PubMedGoogle Scholar
• Hymes LC, Warshaw BL. Five-year experience using sirolimus-based, calcineurin inhibitor-free immunosuppression in pediatric renal transplantation. Pediatr Transplant. 2011;15(4):437–441.
   PubMed Web of Science ®Google Scholar
• Martin S, Powell J, Patel M, et al. Risk of posttransplant lymphoproliferative disorder associated with use of belatacept. Am J Heal Pharm. 2013;70(22):1977–1983.
   PubMed Web of Science ®Google Scholar
• Balandraud N, Guis S, Meynard JB, et al. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis. Arthritis Rheum. 2007;57(5):762–767. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17530675.
   PubMed Web of Science ®Google Scholar
• Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011;70(4):616–623.
   PubMed Web of Science ®Google Scholar
• Carson K, Evens A, Richey E, et al. Progressive multifocal leukoencephalopathy following Rituximab therapy in HIV negative patients: a report of 56 cases from the research on adverse drug event and reports (RADAR) project. Blood [Internet] 2009;113(20):4834–4840. Available from http://www.haematologica.org/cgi/reprint/94/supplement_2/1%5Cnhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed9&NEWS=N&AN=70013293
   PubMed Web of Science ®Google Scholar
• Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) project. Lancet Oncol [Internet]. 2009;10(8):816–824. DOI:10.1016/S1470-2045(09)70161-5
   PubMed Web of Science ®Google Scholar
• Molloy ES, Calabrese CM, Calabrese LH. The risk of progressive multifocal leukoencephalopathy in the biologic era. Rheum Dis Clin North Am [Internet]. 2017;43(1):95–109. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0889857X16300606.
   PubMed Web of Science ®Google Scholar
• Raisch DW, Rafi JA, Chen C, et al. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA’s adverse event reporting system. Expert Opin Drug Saf [Internet]. 2016;15(8):1003–1011. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27268272.
   PubMed Web of Science ®Google Scholar
• McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry [Internet]. 2016;87(2):117–125. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4752634&tool=pmcentrez&rendertype=abstract
   PubMed Web of Science ®Google Scholar
• Jamboti JS. BK virus nephropathy in renal transplant recipients. Nephrology. 2016;21(8):647–654.
   PubMed Web of Science ®Google Scholar
• Manitpisitkul W, Ns W, Haririan A. Immunosuppressive agents as risk factors for BK virus nephropathy: an overview and update. Expert Opin Drug Saf [Internet]. 2010;9(6):959–969. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20521865.
   PubMed Web of Science ®Google Scholar
• Benavides CA, Pollard VB, Mauiyyedi S, et al. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation [Internet]. 2007;84(1):83–88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17627242.
   PubMed Web of Science ®Google Scholar
• Polanco N, González Monte E, Folgueira MD, et al. Everolimus-based immunosuppression therapy for BK virus nephropathy. Transplant Proc [Internet]. 2015;47(1):57–61. DOI:10.1016/j.transproceed.2014.11.008
   PubMed Web of Science ®Google Scholar
• Kling MC, Larian AA, Scordi-Bello I, et al. Fatal influenza A(H1N1) respiratory tract infection in a patient having psoriasis treated with infliximab. Arch Dermatol [Internet]. 2010;146(6):651–654. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20566928.
   PubMedGoogle Scholar
• Bello S, Serafino L, Bonali C, et al. Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents. Reumatismo. 2012;64(5):299–306.
   PubMedGoogle Scholar
• Debruyn J, Fonseca K, Ghosh S, et al. Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomized trial. Inflamm Bowel Dis. 2015;22(3):638–647.
   Web of Science ®Google Scholar
• Berglund A, Willén L, Grödeberg L, et al. The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab. Acta Oncol [Internet] 2014;53(9):1212–1220. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24865118.
   PubMed Web of Science ®Google Scholar
• Bühler S, Eperon G, Ribi C, et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseasesSwiss Med Wkly. 2015;145:w14159.
   Google Scholar
• Van Den Bijllaardt W, Siers HM, Timmerman-Kok C. Seroprotection after Hepatitis A vaccination in patients with. J Travel Med. 2013;20(5):278–282.
   PubMed Web of Science ®Google Scholar
• Askling H, Rombo L, Van VR, et al. Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis : a prospective, open-label, multi-centre study. Travel Med Infect Dis. 2014;12(2):134-142.
   Web of Science ®Google Scholar
• Garcia HM, Wieten RW, Grobusch MP, et al. Response to Hepatitis A vaccination in immunocompromised travelers. J Infect Dis. 2015;212:378–385.
   PubMed Web of Science ®Google Scholar
• Pérez-Díaz CE, Uribe-Pardo E, Calixto O, et al. Review infections with biological therapy : strategies for risk minimization in tropical and developing countries. J Infect Dev Ctries. 2016;12(10):1278–1285.
   Google Scholar
• Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103(3):631–636.
   PubMed Web of Science ®Google Scholar
• Singh H, Nugent Z, Demers AA, et al. Screening for cervical and breast cancer among women with inflammatory bowel disease: a population-based study. Inflamm Bowel Dis. 2011;17(8):1741–1750.
   PubMed Web of Science ®Google Scholar
• Greywoode R, LaFond J, Fine S, et al. Women with inflammatory bowel disease do not receive adequate cervical cancer screening or pregnancy counseling. Inflamm Bowel Dis. 2013;19(1):2007.
   Web of Science ®Google Scholar
• Gallitano SM, McDermott L, Brar K, et al. Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. J Am Acad Dermatol [Internet]. 2016;74(5):974–980. DOI:10.1016/j.jaad.2015.11.043.
   PubMed Web of Science ®Google Scholar
• Cohen C, Horster S, Sander C, et al. Kaposi’s sarcoma associated with tumour necrosis factor α neutralisisng therapy. Ann Rheum Dis [Internet]. 2003;62(7):684. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1754582&tool=pmcentrez&rendertype=abstract.
   PubMed Web of Science ®Google Scholar
• Ursini F, Naty S, Mazzei V, et al. Kaposi’s sarcoma in a psoriatic arthritis patient treated with infliximab. Int Immunopharmacol [Internet]. 2010;10(7):827–828. DOI:10.1016/j.intimp.2010.04.016.
   PubMed Web of Science ®Google Scholar
• Marie I, Guglielmino E. Infections opportunistes non tuberculeuses au cours des traitements par les anti-TNF?? Rev Med Interne [Internet]. 2010;31(5):353–360. DOI:10.1016/j.revmed.2009.04.010.
   PubMedGoogle Scholar
• Roy D, Sin S, Lucas A, et al. mTOR inhibitors block kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis. Cancer Res. 2013;73(7):2235–2246.
   PubMed Web of Science ®Google Scholar